[What do we know about obesity?]

Area of Science:

• Cardiology
• Endocrinology
• Public Health

Background:

• Obesity prevalence is rising globally, linked to increased cardiovascular disease (CVD) risk.
• Body Mass Index (BMI) is a common obesity measure but doesn't account for fat distribution.
• Waist circumference is a superior anthropometric indicator for total and intra-abdominal fat, correlating with metabolic syndrome and CVD risk.

Purpose of the Study:

• To highlight the limitations of BMI in assessing obesity-related cardiovascular risk.
• To emphasize the importance of body fat distribution, particularly android obesity, in metabolic and cardiovascular health.
• To review effective weight reduction strategies and emerging pharmacological interventions.

Main Methods:

• Review of clinical and epidemiological research on obesity, body fat distribution, and cardiovascular risk.
• Analysis of anthropometric indicators, including waist circumference and BMI.
• Examination of molecular mechanisms linking metabolic syndrome to vascular abnormalities.
• Evaluation of behavioral interventions and pharmacological treatments for weight management.

Main Results:

• Waist circumference is a better predictor of intra-abdominal fat and associated metabolic-cardiovascular risks than BMI.
• Android obesity is strongly linked to metabolic syndrome and increased cardiovascular risk.
• Combined lifestyle interventions (diet, exercise, behavior therapy) yield superior long-term weight management outcomes.
• Pharmacological agents like sibutramine, orlistat, and rimonabant offer various mechanisms for weight reduction.

Conclusions:

• Waist circumference is a crucial metric for assessing obesity-related health risks.
• Comprehensive lifestyle interventions are key for sustainable weight loss and maintenance.
• Emerging pharmacological strategies targeting neurotransmitters, fat absorption, or the endocannabinoid system show promise for obesity treatment.